NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.3 Sex hormones and hormone antagonists in malignant disease > 8.3.4 Hormone antagonists > 8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists > Degarelix for treating advanced hormone-dependent prostate cancer - NICE TAG TA404

Degarelix for treating advanced hormone-dependent prostate cancer - NICE TAG TA404

1.1 Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016.

1.2 This guidance is not intended to affect the position of patients whose treatment with degarelix was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta404

Site by Devopa
© Copyright 2019 NHS. All rights reserved.